

4DMedical wins commercial pilot with US Department of Defense

05 May 2023

Highlights

- 4DMedical wins commercial pilot with U.S. Department of Defense
 - Fixed number of scans to be performed on full commercial terms
-

Melbourne, Australia, 05 May 2023: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces another significant milestone in the Company’s commercialisation strategy with the initiation of a commercial pilot at the Military Health System (MHS) within the U.S. Department of Defense.

Military Health System

The MHS supports the U.S. National Defense Strategy by providing a medically ready force, through cutting edge medical research and development. The MHS is one of the largest and most advanced health care institutions in the U.S., with an annual budget of over USD \$50b, providing the 1.3m active military personnel with access to health services across a network of 45 hospitals and inpatient facilities.

Commercial arrangement

The arrangement with the Department of Defense is best characterised as a commercial pilot, and it represents another significant milestone in the Company’s commercialisation strategy. The contractual arrangement involves performing an agreed number of scans on full commercial terms and, if successful, has the potential to grow. While not immediately material from a revenue perspective, it validates the utility of XV Technology® to provide rich respiratory health insights across a range of lung diseases.

4DMedical CEO and Founder Andreas Fouras said:

I am incredibly excited to share our success in winning a commercial pilot with the U.S. Department of Defense. In particular, this major development, side by side with our growing momentum at the VA, allows us to contemplate a vision where 4DMedical is a core part of lung health for all US military personnel, both past and present.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 102
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



Contacts

Corporate

CFO

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Naomi Lawrie

companysecretary@4dmedical.com

Media Enquiries

TCN

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology[®], 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS[®]) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS[™].

XV LVAS[®] and CT LVAS[™] reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.